Cargando…
Revisiting NTRKs as an emerging oncogene in hematological malignancies
NTRK fusions are dominant oncogenic drivers found in rare solid tumors. These fusions have also been identified in more common cancers, such as lung and colorectal carcinomas, albeit at low frequencies. Patients harboring these fusions demonstrate significant clinical response to inhibitors such as...
Autores principales: | Joshi, Sunil K., Davare, Monika A., Druker, Brian J., Tognon, Cristina E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410820/ https://www.ncbi.nlm.nih.gov/pubmed/31551508 http://dx.doi.org/10.1038/s41375-019-0576-8 |
Ejemplares similares
-
Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer
por: Chen, Zijian, et al.
Publicado: (2021) -
Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs
por: Cho, Hanna, et al.
Publicado: (2021) -
Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3 mutation-positive leukemia
por: Agarwal, Anupriya, et al.
Publicado: (2014) -
Bone Marrow Biopsies Revisited: a new dimension for hematologic malignancies
por: Harris, M.
Publicado: (1985) -
Overcoming Gleevec-resistance by blocking oncogene addiction in malignant hematologic cells
por: Pan, Jingxuan
Publicado: (2012)